PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT. The presentation will be available for live streaming and will also be archived for one year on the company’s website. PepGen focuses on advancing next-generation oligonucleotide therapies aimed at severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide (EDO) platform. This platform leverages over a decade of research to enhance the uptake and efficacy of oligonucleotide therapeutics through cell-penetrating peptides.
Details
News Market Reaction – PEPG
The recorded move for PEPG in the trading session of this news was -10.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20th at 8:00am EDT.
The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen’s website. A replay of the event will be archived for one year.
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.
Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com
Media Contact
Sarah Sutton
Argot Partners
PepGen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.